Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease  by Baird, Andrew et al.
BBA Clinical 5 (2016) 66–71
Contents lists available at ScienceDirect
BBA Clinical
j ourna l homepage: www.e lsev ie r .com/ locate /bbac l inUp-regulation of the human-speciﬁc CHRFAM7A gene in inﬂammatory
bowel diseaseAndrew Baird a,⁎, Raul Coimbra a, Xitong Dang a,b, Brian P. Eliceiri a, Todd W. Costantini a
a Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA, USA
b The Key Laboratory of Medical Electrophysiology, Institute of Cardiovascular Research, Sichuan Medical University, Luzhou, China⁎ Corresponding author at: Division of Trauma, Surgica
Care Surgery, Department of Surgery, University of Ca
98896, USA.
E-mail address: anbaird@ucsd.edu (A. Baird).
http://dx.doi.org/10.1016/j.bbacli.2015.12.003
2214-6474/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 23 November 2015
Received in revised form 16 December 2015
Accepted 17 December 2015
Available online 8 January 2016Background: The α7-subunit of the α7-nicotinic acetylcholine receptor (α7-nAChR) is an obligatory
intermediate for the anti-inﬂammatory effects of the vagus nerve. But in humans, there exists a second
gene called CHRFAM7A that encodes a dominant negative α7-nAChR inhibitor. Here, we investigated
whether their expression was altered in inﬂammatory bowel disease (IBD) and colon cancer.
Methods: Quantitative RT-PCR measured gene expression of human α7-nAChR gene (CHRNA7), CHRFAM7A,
TBC3D1, and actin in biopsies of normal large and small intestine, and compared to their expression in biopsies
of ulcerative colitis, Crohn's disease, and colon cancer.
Results: qRT-PCR showed that CHRFAM7A and CHRNA7 gene expressionwas signiﬁcantly (p b .02) up-regulated
in IBD (N = 64). Gene expression was unchanged in colon cancer. Further analyses revealed that there were
differences in ulcerative colitis and Crohn's Disease. Colon biopsies of ulcerative colitis (N = 33) conﬁrmed
increased expression of CHRFAM7A and decreased in CHRNA7 expression (p b 0.001). Biopsies of Crohn's disease
(N= 31), however, showed only small changes in CHRFAM7A expression (p b 0.04) and no change in CHRNA7.
When segregated by tissue source, both CHRFAM7A up-regulation (p b 0.02) and CHRNA7 down-regulation
(p b 0.001) were measured in colon, but not in small intestine.
Conclusion: The human-speciﬁc CHRFAM7A gene is up-regulated, and its target, CHRNA7, down-regulated, in
IBD. Differences between ulcerative colitis and Crohn's disease tie to location of disease.
Signiﬁcance: The appearance of IBD in modern humans may be consequent to the emergence of CHRFAM7A, a
human-speciﬁc α7-nAChR antagonist. CHRFAM7A could present a new, unrecognized target for development
of IBD therapeutics.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The emergence of human-speciﬁc genes (HSG) in the course of
human evolution are presumed to have enabled the adaptation of
humans to new environments and new behaviors [1–9] but their specif-
ic physiological functions are often unknown. The human-speciﬁc
CHRFAM7A gene is a case in point. First, it encodes a uniquely human
and independently regulated subunit of the α7-nicotinic acetylcholine
receptor (α7-nAChR) that regulates neurotransmitter function. There-
fore, it is presumed to affect CNS function. When co-expressed with
α7-nAChR, however, CHRFAM7A is a dominant negative regulator of
neurotransmitter binding to, and activation of, the α7-nAChR, thereby
potentially altering the central nervous system functions of α7-nAChRl Critical Care, Burns and Acute
lifornia San Diego, La Jolla, CA
. This is an open access article underin its regulation of processes like cognition, memory, andmental health
[10–19].
But CHRFAM7A is also widely expressed in leukocytes and epithelial
cells [11,19–21], where it is presumed to regulate the powerful anti-
inﬂammatory effects of α7-nAChR activation [22–24]. Because the acti-
vation of α7-nAChR is an obligatory intermediate for vagus nerve con-
trol of inﬂammation [25], CHRFAM7A in humans must therefore
regulate the anti-inﬂammatory vagus nerve. If so, it raises the possibility
that CHRFAM7A expression in peripheral tissues [20,21] could be asso-
ciatedwith human inﬂammatory disease like, for example, inﬂammato-
ry bowel disease (IBDs).
IBDs have complex molecular etiologies of genetic, epigenetic, mi-
crobial, and environmental origin that present as highly heterogeneous
episodes of gut inﬂammation [26,27], making animal modeling difﬁcult
[28]. Accordingly, the response of IBDs to behavioral, dietary, and ther-
apeutic interventions is often enigmatic, as exempliﬁed by both protec-
tive and deleterious effects of nicotine and nicotine withdrawal on its
remission, recurrence, and treatment [26,27]. Here, we explored thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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expression of the human-speciﬁc and pro-inﬂammatory CHRFAM7A
gene and its anti-inﬂammatory α7-nAChR target [11,19,24,25]
(CHRNA7), could be implicated in IBD.
2. Materials and methods
2.1. Biopsies of inﬂammatory bowel disease and colon cancer
cDNAs in OriGene TissueScan Arrays from characterized biopsies
of ulcerative colitis (CCRT101 and CCRT 102), Crohn's disease
(CCRT101 and CCRT 102), or colon cancer (HCRT104) were used to
assess gene expression in disease (N = 109) and control (N = 19)
tissue biopsies. All characteristics of these specimens are available
online with detailed clinical information, histology slides of each
biopsy, and the quality control data for RNA isolation and cDNA
preparations at California http://www.origene.com/qPCR/Tissue-
qPCR-Arrays.aspx. The original de-identiﬁed tissues were collected
from accredited medical institutions in the United States using IRB-
approved protocols, selected by board-certiﬁed pathologists and
then deposited into the OriGene tissue biorepository along with all
of the available clinical data supporting the pathology diagnoses.
The speciﬁc array plates used contained cDNA synthesized prepared
from RNA extracted from these pathologist-veriﬁed tissues. TheTable 1
Tissue biopsies.
Ulcerative colitis Crohn's disease
Array ID CCRT101/102 CCRT101/102
Biopsies studied 44 42
Normal 11
Disease 33 31
Control biopsies
Location of lesion Colon 8
Small Intestine 3
Gender
Male 7
Female 4
Age (years) 54 (26–89)
Male 56 (26–89)
Female 50 (29–70)
% Mucosa 48% (10–90)
Male 50% (20–85)
Female 44% (10–90)
Disease biopsies
Location of lesion Colon 33 Colon 13
Small Intestine 0 Small Intestine 18
Gender
Male 21 14
Female 12 17
Age (years) 39 (22–76) 38 (19–65)
Male 38 (22–72) 40 (20–64)
Female 45 (26–76) 36 (19–65)
% Mucosa/differentiation* 43% (10–100) 38 (0–00)
Male 43% (10–100) 41 (0–80)
Female 43% (10–95) 35 (10–90)
Pathology
Lesion/tumor (%) 100
Male 100
Female 100
Hypercellular stroma (%) N/A
Male N/A
Female N/A
Hypocellular Stroma (%) N/A
Male N/A
Female N/A
Necrosis (%) 0
Male 0
Female 0quantity of cDNA was normalized, ﬁrst validated with ß-actin at
OriGene and the ﬁndings replicated in the course of the gene expres-
sion studies described here. The Ct value of actin gene expression in
each well was determined in our laboratories was highly consistent
(average 20.89 cycles ± 0.1 (SEM, N = 135)) and the individual
values from each well used to calculate relative gene expression in
each biopsy using the actin primers, as speciﬁcally noted by the
array manufacturer.
2.2. PCR, primers, and the conditions for CHRFAM7A, CHRNA7,
and TBC1D3 analyses
The PCR reaction was performed in 50 μl containing 45 μl PCR blue
mix (Invitrogen), 1 μl of each primer (10 μM), 300 ng cDNA, and 2 μl
water. The cycling conditionswere 94 °C for 4min followed by 35 cycles
of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 60 s, and a ﬁnal extension at
72 °C for 5 min. Ten microliters of each PCR product was resolved on a
2% agarose gel and images were acquired using Alpha Innotech imaging
system. Real-time qPCR was performed in a 25 μl reaction containing
12.5 μl 2× CYBR Green PCR Master Mix (BioRad), 0.5 μl of each primer
(10 μM), 1 μl cDNA, and 10.5 μl water. PCR cycling conditions were
95 °C for 10 min followed by 45 cycles of 94 °C for 25 s, 60 °C for 25 s,
and 72 °C for 40 s. Primer efﬁciency for CHRFAM7A and CHRNA7 were
100% and 94%, respectively.Colon cancer
HCRT104
48
8
40
Colon 8
2
6
78 (60–89)
82 (81–82)
77 (60–89)
N/A
N/A
N/A
Tissue Stage N
Colon l 5
Colon ll 9
Colon lll 16
Colon lV 10
16
24
68 (21–89)
65 (21–82)
70 (45–89)
Well Moderate Poor Un-diff.
10 19 6 5
7 11 4 2
3 8 2 3
71% (25–95%)
69.9 (25–95)
73.7 (40–90)
16% (0–55%)
17.3 (0–55%)
14.4 (0–35%)
1.95% (0–28%)
2.7 (0–28%)
0.9 (0–10%)
4.9% (0–40%)
3.6% (0–40%)
6.6 (0–20%)
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actin using ΔΔCt method and primers provided by the manufacturer of
tissue arrays. Primers for CHRFAM7A were designed to hybridize with
the variant 1 transcript by selecting oligonucleotide sequences bridging
shared CHRFAM7A and CHRNA7 sequences and therefore unique to
CHRFAM7A and not available in CHRFAM7A or CHRNA7A alone.Se
Se
Se
Fig.
biop
indi
gen
(shonse:1. CHRFAM7A and CHRNA7 gene expression in
sies from patients with IBD (panels A–C), ulce
cated, between each other to determine the C
e expression between the control and disease
wn).5′-ATAGCTGCAAACTGCGATA-3′,
nti-sense: 5′-CAGCGTACATCGATGTAGCAG-3′APrimers for CHRNA7 were designed to hybridize with both variant 1
and 2 transcripts of human CHRNA7 by selecting oligonucleotide se-
quences that are present in both variants of human CHRNA7 but absent
from CHRFAM7A.nse: 5′-ACATGCGCTGCTCGCCGGGA-3′,
nti-sense: 5′-GATTGTAGTTCTTGACCAGCT-3′.APrimers for TBC1D3 were selected based on previously published
ﬁndings [29]:nse:H5′-GCATCGACCGGGACGTAAG-3′,
nti-sense: 5′-CCTCCGGGTTGTACTCCTCAT-3′.A2.3. Analyses of gene expression
CHRFAM7A, CHRNA7, TBC1D3, and actin gene expressionweremea-
sured as described above and normalized to that of β-actin or as indicat-
ed, to CHRNA7 expression, in each sample. The fold change in gene
expression was calculated by ΔΔCt method and analyzed using the rel-
ative expression software tool (REST) for group-wise comparisons of
relative expression [30]. The GraphPad program PRISM6 was used for
preparation of ﬁgures.
3. Results and discussion
The characteristics of the commercially available gene expression ar-
rays of human IBD and colon cancer used in these studies are publicly
available http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx and
include information regarding gender, age, tissue of origin, case diagno-
sis from donor institutions, histological sections, and pathology veriﬁca-
tion reports. The latter also includes the percentage of mucosa/
differentiation, lesion, and inﬂammation and are summarized in Table 1.
3.1. CHRFAM7A and the gene encoding human α7-nAChR (CHRNA7) are
differentially expressed in IBD
Initially, quantitative RT-PCR of biopsies (N = 64) from patients
with IBD suggested that there was only a small, albeit signiﬁcant
(p b 0.05) increase in CHRFAM7A gene expression (Fig. 1A) compared
to biopsies from control tissue. In cDNA prepared from these same biop-
sies, there was no signiﬁcant difference in CHRNA7 gene expression
(Fig. 1B) although the ratio of CHRFAM7A/CHRNA7 gene expression
(Fig. 1C) was different in IBD (p b 0.02) compared with controls.
In contrast, when we compared CHRFAM7A and CHRNA7 gene
expression in the two distinct forms of disease represented in IBD (ul-
cerative colitis and Crohn's disease), a signiﬁcant pattern emerged.
First, colon biopsies from patients with ulcerative colitis (N= 33) con-
ﬁrmed the global increase in expression of CHRFAM7A (Fig. 1D), but
now the analyses revealed that there was a concomitant and signiﬁcant
(p b 0.001) decrease in CHRNA7 expression in ulcerative colitis (Fig. 1E).inﬂammatory bowel disease (IBD). Quantit
rative colitis (panels D–F), and Crohn's dise
RFAM7A/CHRNA7 ratio. Relative gene exp
biopsies were measured by REST [30] for gThese changes in ulcerative colitis were also highly signiﬁcant
(p b 0.001) when comparing CHRNA7 expression to that of CHRFAM7A
(Fig. 1F). In Crohn's disease (N= 31), there was a small but signiﬁcant
(p b 0.04) increase in CHRFAM7A gene expression (Fig. 1G) but no sig-
niﬁcant change in CHRNA7 expression (Fig. 1H). As earlier, normaliza-
tion of CHRFAM7A with CHRNA7 expression increased the signiﬁcance
of the difference (p b 0.02, Fig. 1I).
Ulcerative colitis affects colon and not small intestine but Crohn's
disease can affect any portion of the gastrointestinal tract [26,27]. In an-
alyzing the source of biopsy (Fig. 1J, K, and L), we observed a signiﬁcant
(p b 0.02) up-regulation in CHRFAM7A gene expression in colon from
patients with Crohn's disease (Fig. 1J), but therewas also a concomitant
and signiﬁcant (p b 0.001) down-regulation in CHRNA7 (Fig. 1K)
underscored by the signiﬁcant change of CHRFAM7A when normalized
with CHRNA7 (Fig. 1K). In small intestine biopsies of Crohn's disease,
the change in CHRFAM7A (Fig. 1M), CHRNA7 (Fig. 1N) or in the ratio
of CHRFAM7A to CHRNA7 (Fig. 10) was not signiﬁcant.3.2. The changes in CHRFAM7A and CHRNA7 are speciﬁc
We used two approaches to establish speciﬁcity of differential
expression in diseased colon. First, we evaluated the expression of
CHRFAM7A (Fig. 2A and D), CHRNA7 (Fig. 2B and E), and CHRFAM7A-
to-CHRNA7 ratio (Fig. 2C and F) in colon cancer biopsies. No differences
were detected when all colon cancer biopsies were evaluated together
(Fig. 1A, B, C) or when analyzed according to the stage of disease (Fig.
1D, E, F). Second, we evaluated the expression of a second human-
speciﬁc gene called TBC1D3, that is associated with macro-pinocytosis
and epidermal growth factor signaling [29]. There were no differences
in IBD, no differences in either ulcerative colitis or Crohn's disease
when examined separately. There were also no differences in gene ex-
pression of TBC1D3 in biopsies from colon cancer (Fig. 2G, H, I). This
concordance of CHRFAM7A and CHRNA7 expression in colon cancer is
also evident in curated public databases like the Cancer Genome Atlas
(www.cbioportal.org), which enables mining gene expression patterns
in different epithelial cancers. Correlations between CHRFAM7A and
CHRNA7 in these databases are N0.87 (Pearson) and N0.77 (Spearman)
in uterine, stomach, and colorectal cancers). Unfortunately, no analo-
gous public databases with RNAseq data exist for inﬂammatory bowel
disease, Crohn's disease, or ulcerative colitis, although several studies
have evaluated whole genome gene expression [31–33] and found
changes in, and effects of, traditional inﬂammatory products like TNF
and HMBG1 [34,35].
In 2011, Cooper and Kehrer-Sawatzki [8] reported that new human
genes [2,3,5,7–9] are over-represented among genes tied to complex
human disease and more recently [36] described how newly evolved
human genes can drive gene interaction networks associated with criti-
cal phenotypes. It is in this vein that the results presented here suggest
that the up-regulation of pro-inﬂammatory CHRFAM7A in humans
could exacerbate the down-regulation of anti-inﬂammatory α7-nAChR
in IBD. If so, it is interesting to speculate that this pro-inﬂammatory effect
of CHRFAM7A expression is an “off-target” contributor to human IBD
that arose as a function of adaptation (Fig. 2J, K). In this paradigm, a
human-speciﬁc gene like CHRFAM7A could have originally arisen as an
evolutionary pro-inﬂammatory and adaptative response to newly
emerging human behaviors like bipedal walking (trauma) or the
harnessing of ﬁre (burn injury) but retained for CNS activities regulating
neurotransmitter activity. Interestingly, human-speciﬁc responses in
gene expression after trauma, burn, and infection have been previously
described [37], although they remain controversial largely because ofative RT-PCR was used to measure CHRFAM7A and CHRNA7 gene expression in intestinal
ase (panels G–J). Gene expression in each sample was normalized to that of actin or, as
ression was compared to that in control biopsies using the ΔΔCt method. Differences in
roup-wise comparisons and evaluated as either individual plates and after combination
Fig. 2. Changes in CHRFAM7A and CHRNA7 gene expression are speciﬁc for IBD. Quantitative RT-PCR was used to measure CHRFAM7A and CHRNA7 gene expression in biopsies of colon
cancer (panelsA–F) as all biopsies (panelsA–C) or by colon cancer stage (panelsD–F). Gene expression in each samplewas normalized to that of actin or, as indicated, between CHRFAM7A
and CHRNA7 using the ΔCt method. Relative gene expression was then compared to that in control biopsies using the ΔΔCt method. Differences in gene expression between the control
and disease biopsies were measured by REST [30] for group-wise comparisons and no differences were found to be signiﬁcant at p b 0.05. Expression of the human-speciﬁc gene TBCD1
fromall IBD samples (panelG), in Crohn's andulcerative colitis (panelH) or in colon cancer (panel I)were also unchanged. As illustrated inpanel J, newgenes emerge innewenvironments
to adapt to new behaviors like bipedal behavior (trauma) and the harnessing of ﬁre (burn/sepsis) and alter responsiveness. Off-target effects (panel K) for example regulatingα7-nAChR
activity in neurons might prove evenmore important than the original pro-inﬂammatory selection but the sequelae for human disease tied to original (inﬂammation) and unanticipated
(mental health) effects of gene expression.
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the putative adaptive pro-inﬂammatory origin of a hominid gene like
CHRFAM7A may ultimately be ancillary to its physiological signiﬁcance
to human speciation because CHRFAM7A in the brain is tied to reg-
ulating α7-nAChR, a ligand-gated neurotransmitter channel that it-
self regulates human cognition, attention, memory, and mental
health. In this model, the up-regulation of CHRFAM7A in peripheral
tissues of modern humans could reﬂect vestigial pro-inﬂammatory
activity. Such a possible paradigm underscores the importance of
understanding the role of human evolution in the etiology of
human disease, the role of HSGs, and ultimately, their function
when modeling human disease.
On aﬁnal note, thedifferential expression of theCHRFAM7Ahuman-
speciﬁc gene in a prototypic humandisease like IBDunderscores the im-
portance of better understanding the contribution of this class of genes
to the onset, development, and progression human disease when dis-
eases are modeled in experimental animals. With newly emerged
human-speciﬁc genes like ARHGAP11B promoting neocortex expansion
in vivo [40], c20orf203 eliciting differential gene function [41], human-
speciﬁc defensins conferring differential resistance to infection [42],
and CD33 providing cognitive protection [43], it is critical to understand
the possible contributions of newly evolved gene interaction networks
to human disease when they differ in humans from all other species
and create unique phenotypes [36].
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